CA Patent

CA3160126A1 — Method of treating palmoplantar keratoderma

Assigned to Sol Gel Technologies Ltd · Expires 2021-05-14 · 5y expired

What this patent protects

The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epider…

USPTO Abstract

The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGER) inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
CA3160126A1
Jurisdiction
CA
Classification
—
Expires
2021-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Sol Gel Technologies Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.